Menu
EDNA empowers you to take control of your genetic information and unlock its potential value. Securely store, manage, and monetize your DNA data while maintaining complete control, ownership and privacy.
Store your genetic data with military-grade encryption, ensuring your most personal information remains absolutly private, controlled by you alone and secure.
How Secure?Experience the exclusiveness of the personalized medicine revolution. Uncover vital insights into your genetic makeup, allowing you to make informed, proactive decisions for a healthier future.
Personalized ?Participate in research studies and data sharing programs, earning significant rewards for contributing real benefits to scientific advancements.
Rewards?Explore profitable opportunities to invest in DNA-based assets, help advance medicine all while dealing a solidly effective blow to poverty.
Invest in DNA?Revolutions in Genomics: An Update from EDNA
In May 2021, we presented EDNA to the San Diego MIT Enterprise Forum, and since then, EDNA has undergone significant advancements. We have transitioned from PacBio to the cutting-edge Illumina NovSeq X technology, revamped our pricing model, and strategically decided to offer only T2T-CHM13 short-read polished long-read whole genomes. Most notably, we’ve integrated a powerful Neural Network to run VCF files against real-time ClinVar data, enabling groundbreaking capabilities in inference, prediction, annotation, variant classification, genotype assessment, feature extraction, clinical interpretation, pathogenicity prediction, and variant prioritization. These advancements present transformative benefits for researchers and genetic counselors.
The EDNA – F1 Measured Targets (Benefits):
Comprehensive Insights: Utilizing ClinVar data, our model interprets complex genetic variations, providing deep insights into their clinical significance.
Innovative AI Technologies: By combining Graph Neural Networks (GNNs) to capture intricate genetic relationships and Transformers to analyze sequential patterns and long-range dependencies, our AI delivers a richer, more nuanced understanding of genetic data.
Immediate Results: The implementation of gRPC protocol ensures efficient, real-time communication, allowing researchers to obtain prompt analysis results.
Timely Decision-Making: This capability is crucial for rapid clinical decisions, such as diagnosing genetic disorders or developing personalized treatment plans.
Streamlined Workflow: Our automated system for classifying and annotating genetic variants drastically reduces the manual workload for researchers.
Efficient Flagging: The AI swiftly identifies known pathogenic, benign, or novel variants, optimizing lab operation and productivity.
Uncovering Hidden Insights: Our hybrid model reveals previously unnoticed patterns and relationships in genetic data, which traditional methods might miss.
Advancing Research: This capability could lead to the discovery of new genetic markers linked to diseases and other phenotypic traits.
Handling Big Data: Designed for efficiency, our AI can process large volumes of data, making it ideal for extensive genomics projects involving hundreds or thousands of genomes.
Supporting Large Studies: This scalability enables robust population studies and large-scale genomic research initiatives.
We’re excited about these advancements and eager to see how they drive forward the field of genomics, providing powerful tools and insights for both research and clinical applications.
The EDNA – F1 Measured Targets (Benefits):
Comprehensive Insights: Utilizing ClinVar data, our model interprets complex genetic variations, providing deep insights into their clinical significance.
Innovative AI Technologies: By combining Graph Neural Networks (GNNs) to capture intricate genetic relationships and Transformers to analyze sequential patterns and long-range dependencies, our AI delivers a richer, more nuanced understanding of genetic data.
Immediate Results: The implementation of gRPC protocol ensures efficient, real-time communication, allowing researchers to obtain prompt analysis results.
Timely Decision-Making: This capability is crucial for rapid clinical decisions, such as diagnosing genetic disorders or developing personalized treatment plans.
Streamlined Workflow: Our automated system for classifying and annotating genetic variants drastically reduces the manual workload for researchers.
Efficient Flagging: The AI swiftly identifies known pathogenic, benign, or novel variants, optimizing lab operation and productivity.
Uncovering Hidden Insights: Our hybrid model reveals previously unnoticed patterns and relationships in genetic data, which traditional methods might miss.
Advancing Research: This capability could lead to the discovery of new genetic markers linked to diseases and other phenotypic traits.
Handling Big Data: Designed for efficiency, our AI can process large volumes of data, making it ideal for extensive genomics projects involving hundreds or thousands of genomes.
Supporting Large Studies: This scalability enables robust population studies and large-scale genomic research initiatives.
We’re excited about these advancements and eager to see how they drive forward the field of genomics, providing powerful tools and insights for both research and clinical applications.
We hope you enjoy the presentation – but please do keep in mind this content is over 3 years old and in the extremely dynamic worlds of genetics and blockchain things change fast. EDNA is a fluid within a fluid and we are working hard every day to make sure we have the mix just right.
Sign up to our newsletter to receive updates, invitations and access to special promotions.
EDNA, Inc. 2018-2024 – All rights reserved.
30 North Gould Street, Suite 4861, Sheridan, WY 82801